Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is how SVFC will make money! And it is already generating royalities : )
Technology Licensing
IntelliCell will license its suite of technology and protocol to physicians
or surgery centers for use among their patients.
ICBS Lab Technician runs the process ensuring quality control and GMP &
GLP compliance.
OP PORTUNI T Y HIGHL IGHT S
?? Orthopedics: Over 1 Million Hip and knee replacements, 600,000
back procedures performed annually in the U.S. where SVFs could
potentially mitigate the need for surgery.
?? Sports Medicine: A $1.3B addressable market and a key corporate
focus with meaningful partnerships already secured.
?? Periodontal Disease: A $6B addressable market; IntelliCell has
recently completed case studies using SVFs in the treatment of gum
recession showing no need for grafting
SPORTS MEDICINE
Sports Medicine is a key strategic focus for IntelliCell
as it seeks to build broad brand awareness among
both professional and non-professional athletes.
?? IntelliCell’s efforts led by Dr. James Andrews of the
Andrews Sports Medicine and Orthopedic Centers.
?? Planned multi-center clinical study exploring SVF’s
impact on osteoarthritis of the knee.
MARKET OPPORTUNITY
?? 17,000 Professional Athletes in the U.S.
?? 50,000 NCAA Division I Athletes in the U.S.
???? Millions of amateur athletes and aging boomers
REVENUE MODEL FOR LICENSING
?? $150,000 in upfront licensing fees for
equipment, installation, and training.
?? Yields high margin revenues for IntelliCell.
?? $1,000 in per procedure fees to IntelliCell.
?? Two procedures per week per lab
generates $100,000 in annual revenues
for IntelliCell.
?? IntelliCell estimates 100 labs will be
operational by year-end 2013.
Licensing Partners: Territories
IntelliCell has licensed its Technology to International partners for large
upfront payments and ongoing royalties.
SECURED PARTNERS
?? Licensed by RegenaStem in Canada (operating as IntelliCell
BioSciences of Canada) for $500,000 upfront and a 30% share of
revenues.
?? Licensed by Cell-Innovations, Pty Limited in Australia for $700,000
upfront and a 12.5% share of revenues.
PROSPECTIVE PARTNERS
?? Middle East led by Saudi Arabia
?? Thailand
?? Malaysia
?? Indonesia
ACTIVE PARTNERSHIP DISCUSSIONS
?? Wound Care: The Global wound care market generated $6.2B in 2010.
Over the course of the next decade, demand for advanced wound care will
increase due to an increasing prevalence of chronic wounds as diabetes and
obesity rates increase.
?? Heart Disease: Cytori, an IntelliCell peer that harvests stem cells from
adipose tissue using enzymes, is sponsoring three European clinical trials to
evaluate the use of adipose-derived stem and regenerative cells in the
treatment of acute myocardial infarction and chronic myocardial ischemia
and recently received FDA approval for IDE.
?? Adipose stem cell heart attack trial data published in the Journal of
American College of Cardiology in January 2012.
?? IntelliCell is in discussion with several partners who may desire a
substantially similar solution that leverages IntelliCell technology.
Centers of Excellence
Centers of Excellence are IntelliCell
managed locations where patients can
receive SVF treatments.
?? First Center to open in April 2012 offering
cosmetic and dermatologic procedures.
?? Centers of Excellence receives $10,000 per
patient per procedure versus $1,000 in the lab
sales model.
?? Centers of Excellence receives $2,500 per
procedure when other physicians utilize the
facility.
PLANNED CENTERS
?? Beverly Hills, CA
?? Miami, FL
?? Houston, TX
SVF Cryo-Storage
IntelliCell’s Cryo-Storage Service will create a large stream of highmargin
recurring revenues.
?? $500 for initial collection.
?? $200 per dose per year for storage.
?? $1,000 for removal from storage and shipment to physicians for use
by patient.
OPPORTUNITY
?? 500,000 liposuction procedures performed annually, an ideal source
of customers who have ready access to adipose tissue.
?? Examining acquisitions and joint ventures opportunities with several
prominent cryo-storage companies.
Human Body's Fat Seen As best Source of Stem Cells For Regenerative Therapies
The human body’s usually unwanted fat tissue may end up, after all, as a very useful contributor to regenerative medicine, a rapidly expanding set of innovative medical technologies that restore human function by enabling the body to repair, replace, or regenerate damaged, aging or diseased cells, tissues, and organs. The use of autologous or one’s own fat, which in itself contains large amounts of various types of stem cells, is a new frontier in medicine that’s widely accepted in Europe and Asia.
Several young biotech firms are already using an adult’s own stem cells not for cosmetic effects alone but to meet the rising demand for anti-aging and rejuvenation treatments, as well as addressing more serious medical conditions, including acute cardiovascular disease, chronic fatigue syndrome, inflammation, arthritis, and hypertension.
Certainly the cell therapy industry is showing great potential for huge growth. “We note that the current business fundamentals in cosmetic and reconstructive surgery are improving,” says Jason Napolitano, analyst at Zacks Investment Research. The leader in the group is Cytori Therapeutics (CYTX), which develops and makes medical products and devices for regenerative medicine.
A smaller biotech firm, IntelliCell Biosciences (SVFC), is a new entry in the game but has made a technological breakthrough in manufacturing “stromal vascular fraction” (SVF) cells derived from a body’s fat that can be used to treat ailments or rejuvenate diseased or damaged tissue and cell function. Under the FDA’s Rule 361, IntelliCells is authorized to commercially sell its SVF stem cells in the U.S. IntelliCell has applied for a patent on the use of ultrasonic cavitaton to break up fat tissue to dramatically increase the yield of SVF cells from just 2 oz. of fat.
Cytori has an array of products, including a device called Celution, which processes a patient’s adipose-derived stem and regenerative cells, for use in cosmetic and reconstructive surgery. Cytori markets a $100,000 machine to physicians to process 6 oz. of fat that in two hours derives about 50 million SVF cells. The machine breaks up the fat cells through a chemical enzyme. Cytori has also developed a Celution system, which has completed two clinical trials, for applications in cardiovascular disease, wound healing, gastronomical intestinal disorders and urinary incontinence.
“We continue to be positive on Cytori,” says Napolitano, as it is nearing that “inflection point” in the business where the clinical data and new product offerings are starting to show up in the revenue line. The upside to its story, he says, comes as the company transitions from the current cosmetic-and-reconstructive surgery approach to regenerative medicine specifically in the area of both acute and chronic cardiovascular disease.
In the case of IntelliCell, the company focuses more on producing large amounts of SVF cells from just a small amount of autologous fat cells of about 2 oz. IntelliCell CEO Dr. Steven Victor found a method that allows the use of ultrasonic cavitation to increase the yield of SVF cells. By using the ultrasonic method, Dr. Victor says he turns the 2 oz. of fat into SVF stem cells of between 0.5 billion and 1.4 billion. The process takes just about 30 minutes at IntelliCell’s labs. Doctors then use the SVF cells for treatment of various ailments, from regenerative cosmetic procedures to repairing tissues involving damaged knees, back injuries, migraine headaches, and multiple sclerosis.
“It is very apparent that a person’s fat cells are the best source of stem cells, which are stored inactively in one’s fat tissues, for use in the fast growing field of regenerative medicine,” says Dr. Victor, a practicing dermatologist for more than 20 years. He says IntelliCell’s proprietary process makes the most cells from the least amount of fat more efficiently and less expensive than any other competing products.
A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.
A GAME CHANGER IN REGENERATIVE MEDICINE
Says Dr. Victor: “We feel our technology is a game changer in the field of regenerative medicine and that SVF cells show incredible promise for a wide range of clinical uses.”
Another Board member who is learning under Dr. James Andrews
Joshua G. Hackel M.D.
Primary Care Sports Medicine| Andrews Primary Care Sports Medicine
Dr. Joshua Hackel is a primary care sports medicine physician at The Andrews Institute, an affiliate of Baptist Health Care. Because he's an employed physician, Dr. Hackel is also a proud part of the Baptist Medical Group network of quality, caring physicians serving the greater Pensacola area.
Medical Education
American University of the Caribbean
Internship
Columbus Regional Medical Center
Residency
Columbus Regional Medical Center
Fellowship
American Sports Medicine Institute (ASMI) with Dr. James Andrews
Board Certifications
Sports Medicine
Family Practice
Major Publications
Hackel JG, Nicolais V, Adolescent with Rash, Photo Quiz. Am Fam Physician, August 2004
Hackel JG, Verma S, Syncope in Athletes: A Guide to Getting Them Back On Their Feet. The Journal of Family Practice, July 2007; 56(7):545-550.
Hackel JG, Asthma Overview. Athletic Therapy Today, 2004; 9(2):28-29.
Andrews JR, Hackel JG. The Thrower’s Exostosis Pathophysiology and Management. Techniques in Shoulder and Elbow Surgery, 2004; 5(1):44-50.
Scholarly Service Honors
Fellow, American Academy of Family Physicians
Academic Appointments
Clinical Associate Professor Florida State School of Medicine
Clinical Associate Professor University of West Florida
Society Memberships
American Medical Society of Sports Medicine
American College of Sports Medicine
American Medical Association
Florida Medical Association
Team Affiliations
Northview High School team physician
University of West Florida athletics team physician
Intellicell's partner in Canada.
The RegenaStem Cellular Treatment Centers will utilize the patented IntelliCell Inc. proprietary
procedures to harvest and deliver to patients Autologous Homologous SVF to treat degenerative joint
disease of the upper and lower limb with a focus on the hip, shoulder and knee.
There is a nice case study in there as well about Regeneration of human bones in hip osteonecrosis
and human cartilage in knee osteoarthritis with
autologous adipose-tissue-derived stem cells (SVFC):
a case series
http://www.regenastem.com/documents/RegenaStem_Health_Canada_Compliance_Proposal_Oct24.pdf
Did anyone know that svfc signed exclusive with PAWS? What a huuuuggggee Market! people care a lot for their pets.
The PAWS Pet Company, Inc. Announces Exclusive License Agreement With IntelliCell BioSciences, Inc
The PAWS Pet Company, Inc. (OTCQB: PAWS) (OTCPK: PAWS) or “the Company”, the innovative pet services company, today announced it has entered into an exclusive license agreement with IntelliCell BioSciences, Inc., “IntelliCell”, (OTCPK: SVFC) a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells. Per the terms of the agreement, The PAWS Pet Company is to exclusively market and sell IntelliCell’s SVF solution in the veterinary market.
According to Hoovers, the U.S. veterinary services industry has annual revenues estimated at $25 billion.
“This is an important step in the development of the Company,” said Dan Wiesel, Chairman and CEO of The PAWS Pet Company. “This exclusive world-wide license extends our service offering beyond the pet transportation marketplace, into the fast growing market for regenerative medicine for animals. Through our trusted position with both Pet Parents and Veterinarians, we will introduce a technology that we believe will improve the wellbeing of pets.”
Dr. Steven Victor, Chairman and CEO of IntelliCell added, “We are pleased to be working with The PAWS Pet Company in bringing our leading SVF solution to the treatment of animals. The benefits of SVF in providing stem cell counts and viability checks for each specimen processed, as well as enhanced quality and quantity of the stem cells produced, will now be available to pets.”
Dr. Jeff Werber, Director of Veterinary Services with The PAWS Pet Company commented, “SVF is a proven treatment for a number of conditions including osteoarthritis, tendon repair, ligament injuries and other traumatic and degenerative diseases. The higher cell count from a smaller tissue sample means that Pets have a faster road to recovery with SVF compared to legacy enzyme-based stem cell treatments.”
This is amazing! Wasn't around for few days and BOOOOOM!
Good Job All!
Below is the question I asked Nick yesterday after letter was sent out : This is not the whole email for sure but in regards to audit and uplisting.
Will we still get audited Fins and possible uplisting by August? Is this still on schedule?
Answer:
Kevin Yes, it is definitely still on the schedule. 100%.
Nicholas Chieco
Chief Executive Officer & Chairman of the Board of Directors
NorthStar Global Business Services, Inc.
MedGen, Inc. (Wholly Owned Subsidiary)
A Public Company (PinkSheets: MDIN)
20 Peachtree Ct. Ste 103 | Holbrook, NY 11741
TF: 1-877-571-4387
FX : 1-877-571-6184
nchieco@northstarbb.com
So in short, You either believe him or you don't! I believe and will hold and buy on dips. This Company has done things in 6-12 months that is way more than your typical Penny play. Whether or not you give credit to Nick is up to you and your investing strategy. There are things that Nick cannot mention and to be honest, is not required to. Nick keeps us informed and that is all that matters in the short term. The long term however we are going to make a return on our investment. IMO
$MDIN
From Intellicell
Kevin
Thank you for taking a stake in Intellicell. We are committed to bringing all shareholders value and look to advance the company to one of the big boards as soon as we can and we are always developing new and better technology and always file patents to protect our IP and as stated in our website we are looking to doing FDA IND for different disease entities.
We have exciting news coming in the new future for all our shareholders.
Steven Victor MD
Chairman/CEO
Intellicell Biosciences Inc
460 Park Avenue 17th Floor
New York, NY 10022
212-249-3050 Regen Medical PC
Cell 917-459-8252
Svictor@intellicellbiosciences.com
www.intellicellbiosciences.com
Www.regenmedicalpc.com
Www.victordermatologyandrejuvenation.com
Just got another 205,000 shares on the ASK. Going to be big boys!
I respect you're comments Budnik1. The fact of the matter is when this company went through some rough times over the last 2 years they did not stop working on clinical trails and patents etc... A lot of the stuff being posted is still very relevant and just now coming into play and coming to fruition. The deals that were done, the labs opening, the trials completed, the Licensing, the royalties, the patents filed, the advisory board implemented, the board of directors installed etc... all happened in anticipation of what we will see this year or so.
It has definitely been a lag from PR's in 2011/2012 till now but that is the beauty of this stock which has allowed us all to buy in to at these prices. Good luck to you and hope you own shares.
Good luck today all!
SVFC
Best post today! Lol
WOW! Great day all SVFC team. Hope you are right about the filings, this will be a huge boost to side liners confidence. Some are really picky when or when not to get in this one. Not me, I am staying with this one until my zip code changes... Lol
Nice Find BC
Maxim Group Issues Stem Cell Sector Report on IntelliCell BioSciences Based on Treatment Process
Jul 08, 2013 (ACCESSWIRE via COMTEX) -- NEW YORK, July 08, 2013 (eTeligis via ACCESSWIRE) -- IntelliCell BioSciences, Inc. (OTCPINK: SVFC), a developer of novel, patented technology used to isolate stromal vascular fraction cells (stem cells) from adipose (fat) tissue. These cells are used to address the regenerative, curative and preventative conditions of disease, announced New York based Maxim Group has issued a research opinion on stem cell sector, and our position within the industry.
Jason Kolbert, the research analyst at Maxim Group commented in his report, "IntelliCell's position on the legal/regulatory status of SVFC (stromal vascular fraction cells) is that the product is a human cell, tissue, and cellular and tissue-based product ("HCT/Ps") and is regulated under the regulations created under 21 C.F.R. § 1271. The Company maintains that the SVFC product falls within the exemption from FDA regulation found under 21 C.F.R. § 1271.15(b). This is because the HCT/Ps are removed from and reintroduced into the same patient during the same surgical procedure as that term is used in the practice of medicine. The cells that are reintroduced are exactly the same cells (i.e., "such cells") as the cells removed from the autologous patient. Thus, the SVFC product falls under an exemption to FDA regulation."
"Alternatively, even if the SVFC product is not exempt under 21 C.F.R. 1271.15(b), the company maintains that it meets the requirements in 21 C.F.R. § 1271.10(a) for regulation solely under PHS Act § 361 and Part 1271 as a "361 HCT/P" and not as a drug, device, and/or biologic requiring an approved application. Under that section of the regulation, HCT/Ps that are from an autologous source, minimal manipulation, and for homologous use, and do not include added components (with some minor exceptions) are exempt from FDA pre-approval as a drug."
"Under these guidelines IntelliCell Biosciences is empowering clinicians to treat patients today for everything from orthopedic injuries to multiple sclerosis. The company has treated over 300 patients and in some cases with dramatic results. We went so far as to review patients stories and case histories, publications and even met with the company's attorneys (ex-FDA reviewers) to understand the definitions of minimally manipulated and the legal guidelines by which the company's process allows physicians to treat patients. We left believing that this is the only company, at the moment that qualifies with a process that meets current guidelines."
I would love to be here this week:
Intellicell will have space here.
July 11-13th
https://www.sportsmed.org/uploadedFiles/Content2/Industry/Exhibiting_Opportunities/AOSSM2013InvitationtoExhibitFINAL.pdf
TCA Global Credit Master Fund Closes on $2 MM Financing facility for IntelliCell BioSciences Inc.
TCA Global Credit Master Fund today announced it has entered into a $2 Million CEF; committed equity facility with IntelliCell BioSciences (SVFC.PK). Under the terms of the Agreement, TCA Fund will supply the financing in a series of pre-set tranches to the company, with the initial drawdown set at USD 500,000.
The CEF has been provided through TCA Global Credit Master Fund (“TCA Fund”), which seeks to provide financing to small, growing, private and listed companies.
TCA Global Credit Master Fund has provided financing to allow IntelliCell BioSciences, the company, to spur its growth, as well as allow them to take advantage of additional opportunities in their field of regenerative medicine.
Dr. Steven Victor, the Chairman and CEO of the company has a unique approach, “IntelliCell™ is pioneering a new proprietary medical process that results in acquiring Vascular Fraction Cells (VFC). VFC is also known as stromal vascular fraction. VFC cells are known to contain significant numbers of various cell types including adult stem cells, endothelial cells, fibroblast cells, red blood cells, and much more. VFC type cells are in research projects and in clinical trials around the world.”
Based in NY, NY “IntelliCell was formed to take a leading role in the rapidly expanding regenerative medicine field. IntelliCell is fully committed to an ethical and supportive role in providing the tools to physicians and patients to fight some of the most serious disease conditions with very high levels of unmet clinical needs.”
TCA Fund Management Group manages the TCA Global Credit Master Fund and acts as an advisor to countless small companies from its offices in the United States, United Kingdom, and Australia. TCA Fund is a short duration, absolute return fund specializing in senior secured lending to small, mainly listed companies in the U.S., Canada, Western Europe and Australia. The team has a level of domestic and cross-border expertise, long-standing experience, and funding innovations, as is reflected in the number of transactions completed. This is a specialist business with an investment angle which fills an important finance gap in many leading markets. TCA Global Credit Master Fund provides a unique conduit for investors seeking steady, uncorrelated returns in the SME universe.
Seattle, we have a great group of investors here for the same reason..."To make money" Team, do not let the "Snorts" in to rob you of you're shares. I have seen it way too much on other boards where the DD fraud team tries to rescue us from our poor decisions! Let the fact stand that this Company is clearly reviving itself and will be relevant for years to come. Good Luck to the true investors on this board.
This is how SVFC will make money! And it is already generating royalities : )
Technology Licensing
IntelliCell will license its suite of technology and protocol to physicians
or surgery centers for use among their patients.
ICBS Lab Technician runs the process ensuring quality control and GMP &
GLP compliance.
OP PORTUNI T Y HIGHL IGHT S
?? Orthopedics: Over 1 Million Hip and knee replacements, 600,000
back procedures performed annually in the U.S. where SVFs could
potentially mitigate the need for surgery.
?? Sports Medicine: A $1.3B addressable market and a key corporate
focus with meaningful partnerships already secured.
?? Periodontal Disease: A $6B addressable market; IntelliCell has
recently completed case studies using SVFs in the treatment of gum
recession showing no need for grafting
SPORTS MEDICINE
Sports Medicine is a key strategic focus for IntelliCell
as it seeks to build broad brand awareness among
both professional and non-professional athletes.
?? IntelliCell’s efforts led by Dr. James Andrews of the
Andrews Sports Medicine and Orthopedic Centers.
?? Planned multi-center clinical study exploring SVF’s
impact on osteoarthritis of the knee.
MARKET OPPORTUNITY
?? 17,000 Professional Athletes in the U.S.
?? 50,000 NCAA Division I Athletes in the U.S.
???? Millions of amateur athletes and aging boomers
REVENUE MODEL FOR LICENSING
?? $150,000 in upfront licensing fees for
equipment, installation, and training.
?? Yields high margin revenues for IntelliCell.
?? $1,000 in per procedure fees to IntelliCell.
?? Two procedures per week per lab
generates $100,000 in annual revenues
for IntelliCell.
?? IntelliCell estimates 100 labs will be
operational by year-end 2013.
Licensing Partners: Territories
IntelliCell has licensed its Technology to International partners for large
upfront payments and ongoing royalties.
SECURED PARTNERS
?? Licensed by RegenaStem in Canada (operating as IntelliCell
BioSciences of Canada) for $500,000 upfront and a 30% share of
revenues.
?? Licensed by Cell-Innovations, Pty Limited in Australia for $700,000
upfront and a 12.5% share of revenues.
PROSPECTIVE PARTNERS
?? Middle East led by Saudi Arabia
?? Thailand
?? Malaysia
?? Indonesia
ACTIVE PARTNERSHIP DISCUSSIONS
?? Wound Care: The Global wound care market generated $6.2B in 2010.
Over the course of the next decade, demand for advanced wound care will
increase due to an increasing prevalence of chronic wounds as diabetes and
obesity rates increase.
?? Heart Disease: Cytori, an IntelliCell peer that harvests stem cells from
adipose tissue using enzymes, is sponsoring three European clinical trials to
evaluate the use of adipose-derived stem and regenerative cells in the
treatment of acute myocardial infarction and chronic myocardial ischemia
and recently received FDA approval for IDE.
?? Adipose stem cell heart attack trial data published in the Journal of
American College of Cardiology in January 2012.
?? IntelliCell is in discussion with several partners who may desire a
substantially similar solution that leverages IntelliCell technology.
Centers of Excellence
Centers of Excellence are IntelliCell
managed locations where patients can
receive SVF treatments.
?? First Center to open in April 2012 offering
cosmetic and dermatologic procedures.
?? Centers of Excellence receives $10,000 per
patient per procedure versus $1,000 in the lab
sales model.
?? Centers of Excellence receives $2,500 per
procedure when other physicians utilize the
facility.
PLANNED CENTERS
?? Beverly Hills, CA
?? Miami, FL
?? Houston, TX
SVF Cryo-Storage
IntelliCell’s Cryo-Storage Service will create a large stream of highmargin
recurring revenues.
?? $500 for initial collection.
?? $200 per dose per year for storage.
?? $1,000 for removal from storage and shipment to physicians for use
by patient.
OPPORTUNITY
?? 500,000 liposuction procedures performed annually, an ideal source
of customers who have ready access to adipose tissue.
?? Examining acquisitions and joint ventures opportunities with several
prominent cryo-storage companies.
Do the new investor's really want to be sitting on the sidelines when this takes off? This all takes time, SVFC fell from the Nasdaq as they were working on Patents, new Clinical trials, Licensing contracts etc... They are back and time to move back up!
IntelliCell's fat-derived stem cells termed "technological breakthrough" in Forbes
IntelliCell BioSciences (OTCBB:SVFC) has made a technological breakthrough into the regenerative medicine field, according to blog entry in Forbes.
The company, through its proprietary technology, processes stromal vascular fraction (SVF) stem cells, derived from one's own body fat.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for anti-aging effects, as well as for the treatment of more serious conditions like arthritis, congestive heart failure, gum recession, and wound healing.
IntelliCell's SVF cells can be used to treat certain conditions, or rejuvinate damaged tissue and cell function. The company, which under the FDA is authorized to commercially sell its SVF cells, has also applied for a patent on its use of ultrasonic cavitations to break up fat cells, which increases the number of SVF stem cells that can be extracted from just two ounces of fat to between 500 million and 1.4 billion, Forbes said.
The company's technique takes approximately 30 minutes, costs less than other stem cell extraction products, and the stem cells can be returned to a patient’s doctor in the same day.
"It is very apparent that a person’s fat cells are the best source of stem cells, which are stored inactively in one’s fat tissues, for use in the fast growing field of regenerative medicine," IntelliCell CEO, Dr. Steven Victor told Forbes.
Forbes noted that IntelliCell's technology can produce an average of 10 times the number of stem cell-containing SVF cells as traditional methods, which require the use of enzymes, according to a study of the company's technology by a unit of Merck AG.
Indeed, these fat stem cells have similar potential to embryonic stem cells in their pluripotency, and are from a source that involves no moral or ethical issues, as well as no chemical additives required for digestion of the tissue.
In the aesthetic world, the use of autologous adipose, or fat, stem cells has become widely accepted in Europe and Asia. Since the US FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
IntelliCell has also treated more than 100 patients this year alone, Forbes said, including the wife and daughter of MAZ Capital Advisors' president, and IntelliCell shareholder, Walter Schenker. Each underwent a successful treatment at an IntelliCell lab for knee ailments, Forbes cited.
Wonder when we will get more news about these clinical trials? Just another huge development for SVFC
IntelliCell has developed a proprietary treatment methodology using its autologous (your own) cellular therapy that includes adult stem cells that have demonstrated regenerative capabilities in anecdotal studies of patients treated. According to the American Diabetes Association, there are "over 65,000 lower limb amputations performed in the United States" as a direct consequence of diabetes and hundreds of thousands of diabetes related amputations globally.
http://www.prnewswire.com/news-releases/intellicell-biosciences-announces-clinical-study-for-diabetic-critical-limb-ischemia-169603696.html
IntelliCell BioSciences, Inc Announces Powerful Collaboration with Numoda Corporation
http://www.businesswire.com/news/home/20111213006100/en/IntelliCell-BioSciences-Announces-Powerful-Collaboration-Numoda-Corporation
And yes, Numoda lists Intellicell on their website!
I believe this may be the path to Pfizer. IMO
Dr. Fisch, “I believe that the promise of Regenerative Medicine for patients suffering from a number of urological disorders including erectile dysfunction may become an important part in the practice of medicine. This is an exciting time in medicine and I am looking forward to working with cutting edge technologies like IntelliCell’s and improving the clinical outcomes of my patients.” - See more at: http://investorstemcell.com/stem-cell-research/intellicell-biosciences-announces-the-addition-of-harry-fisch-md-as-director-of-urology/#sthash.u2UWR361.dpuf
http://www.harryfisch.com/about-harry-fisch.html
It wasn't that long ago when we were at $3-4 per share
IntelliCell BioSciences Out to Shake Up Regenerative Medicine With Disruptive Technology and Game Plan
The regenerative medicine industry is starting to take notice, but it appears investors are too.
BioMedReports first told readers about this company in a report from the Rodman & Renshaw Conference, and shares have climbed from $3 to over $4 since then. Even in these very anemic market conditions, speculators are starting to take positions after hearing about the potential of the IntelliCell platform.
In addition, the Company just announced that they executed an exclusive supply and sale agreement with Millipore Corporation, a global leader in innovative tools and technologies for bio-manufacturing and life science research, to sell and distribute the guava® flow cytometry platform into the area of stromal vascular fraction.
The collaboration with Millipore is expected to streamline the development of IntelliCell's tissue processing centers throughout the United States as it continues to expand and experience growth in demand for the cells it is able to source from fatty tissue.
As we understand it, the company is rapidly expanding the number of centers throughout the United States and multiple positive announcements should follow. These very unique centers will offer patients the opportunity to use their own adipose (fat) stem cells for treatments as prescribed by their own doctors. Under FDA 361, patients are allowed to use their own stem cells for just about any indication, so long as the use of those cells is autologous (a situation in which the donor and recipient are the same person), the stem cells are minimally manipulated, and the procedure takes place during the same office visit. Even without FDA approval -- which can take years -- IntelliCell™ BioScience aims to work within FDA 361 guidelines and claims that they are fully FDA Compliant on their website and presentation materials.
As we told you in our report, this company represents a game changing opportunity for U.S. based patients to undergo various stem cell therapies using their own stem cells without having to travel abroad or wait for further FDA approvals.
BioMedReports expect that this company -- already one of the only true revenue generating stem cell plays in the market -- will surpass the $30+ million in revenues generated last year by a privately held company based in Plymouth, Mass called Harvest Technologies Corporation.
That company was in the process of commercializing a far more painful (and arguably less effective), point-of-care technology with doctors. Using the Harvest Technology platform, physicians harvested stem cells from a patient's own bone marrow. Harvest was recently acquired by a U.S. subsidiary of Japan's Terumo Corporation -- one of the world's leading medical device manufacturers with $3.4 billion in sales and operations in more than 160 countries in a stock for stock transaction worth $70 million.
The market potential for IntelliCell BioSciences is far more attractive, and we are hearing rumors that various sports franchises may be looking to treat the injuries of pro athletes using the IntelliCell platform within the offices of their own team doctors. No surprise if true, since they have pro sports teams physicians on their advisory board.
The use of autologous adipose stem cells for a growing variety of indications may appear new and exciting in medicine here in the U.S, but the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the U.S. FDA published its laws on autologous stem cells the field has expanded rapidly. If you are looking for a stem cell play that isn't going to make you wait 5+ years for FDA approval, this may be it.
A new report featuring more information about IntelliCell BioSciences, Inc.may be read at:
http://biomedreports.com/2011092879492/regenerative-medicine-industry-taking-notice-of-intellicell-biosciences.html
In addition, investors may access BioMedReports' new complete FDA Calendar and database of clinical trials and world-wide regulatory decisions for use as a tool in more profitable trading by visiting:
http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports
Waiting on a IND (Investigational New Drug) as well in addition to Patent.
IntelliCell BioSciences has completed the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. The company provides product today to ReGen Medical, and in doing so is building fantastic database of patient experience that will be used to focus on clinical applications.
Human Body's Fat Seen As best Source of Stem Cells For Regenerative Therapies
The human body’s usually unwanted fat tissue may end up, after all, as a very useful contributor to regenerative medicine, a rapidly expanding set of innovative medical technologies that restore human function by enabling the body to repair, replace, or regenerate damaged, aging or diseased cells, tissues, and organs. The use of autologous or one’s own fat, which in itself contains large amounts of various types of stem cells, is a new frontier in medicine that’s widely accepted in Europe and Asia.
Several young biotech firms are already using an adult’s own stem cells not for cosmetic effects alone but to meet the rising demand for anti-aging and rejuvenation treatments, as well as addressing more serious medical conditions, including acute cardiovascular disease, chronic fatigue syndrome, inflammation, arthritis, and hypertension.
Certainly the cell therapy industry is showing great potential for huge growth. “We note that the current business fundamentals in cosmetic and reconstructive surgery are improving,” says Jason Napolitano, analyst at Zacks Investment Research. The leader in the group is Cytori Therapeutics (CYTX), which develops and makes medical products and devices for regenerative medicine.
A smaller biotech firm, IntelliCell Biosciences (SVFC), is a new entry in the game but has made a technological breakthrough in manufacturing “stromal vascular fraction” (SVF) cells derived from a body’s fat that can be used to treat ailments or rejuvenate diseased or damaged tissue and cell function. Under the FDA’s Rule 361, IntelliCells is authorized to commercially sell its SVF stem cells in the U.S. IntelliCell has applied for a patent on the use of ultrasonic cavitaton to break up fat tissue to dramatically increase the yield of SVF cells from just 2 oz. of fat.
Cytori has an array of products, including a device called Celution, which processes a patient’s adipose-derived stem and regenerative cells, for use in cosmetic and reconstructive surgery. Cytori markets a $100,000 machine to physicians to process 6 oz. of fat that in two hours derives about 50 million SVF cells. The machine breaks up the fat cells through a chemical enzyme. Cytori has also developed a Celution system, which has completed two clinical trials, for applications in cardiovascular disease, wound healing, gastronomical intestinal disorders and urinary incontinence.
“We continue to be positive on Cytori,” says Napolitano, as it is nearing that “inflection point” in the business where the clinical data and new product offerings are starting to show up in the revenue line. The upside to its story, he says, comes as the company transitions from the current cosmetic-and-reconstructive surgery approach to regenerative medicine specifically in the area of both acute and chronic cardiovascular disease.
In the case of IntelliCell, the company focuses more on producing large amounts of SVF cells from just a small amount of autologous fat cells of about 2 oz. IntelliCell CEO Dr. Steven Victor found a method that allows the use of ultrasonic cavitation to increase the yield of SVF cells. By using the ultrasonic method, Dr. Victor says he turns the 2 oz. of fat into SVF stem cells of between 0.5 billion and 1.4 billion. The process takes just about 30 minutes at IntelliCell’s labs. Doctors then use the SVF cells for treatment of various ailments, from regenerative cosmetic procedures to repairing tissues involving damaged knees, back injuries, migraine headaches, and multiple sclerosis.
“It is very apparent that a person’s fat cells are the best source of stem cells, which are stored inactively in one’s fat tissues, for use in the fast growing field of regenerative medicine,” says Dr. Victor, a practicing dermatologist for more than 20 years. He says IntelliCell’s proprietary process makes the most cells from the least amount of fat more efficiently and less expensive than any other competing products.
A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.
A GAME CHANGER IN REGENERATIVE MEDICINE
Says Dr. Victor: “We feel our technology is a game changer in the field of regenerative medicine and that SVF cells show incredible promise for a wide range of clinical uses.”
Alright, one more. I will be adding more on the ASK in the AM.
OK, SVFC is like a Drug addiction....lol I have to stop and control myself for now. Going to fire up the grill and jump in the pool! Have a great day all!(Even the (-) posters.
Friday is almost here....
We were here just 1 year ago. This Company is heading back to the old days with more and better Technology along with Licensing agreements!
Shares of the tightly held IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK) (Pinksheets: SVFC.PK) have been starting to climb since announcing their arrival as a disruptive stem cell harvesting technology firm just a few short weeks ago. The regenerative medcine industry is starting to take notice, but it appears investors are too.
BioMedReports first told readers about this company in a report from the Rodman & Renshaw Conference, and shares have climbed from $3 to over $4 since then. Even in these very anemic market conditions, speculators are starting to take positions after hearing about the potential of the IntelliCell platform.
In additon, the Company just announced that they executed an exclusive supply and sale agreement with Millipore Corporation, a global leader in innovative tools and technologies for bio-manufacturing and life science research, to sell and distribute the guava® flow cytometry platform into the area of stromal vascular fraction.
Forbes: Human Body’s Fat Seen As best Source of Stem Cells For Regenerative Therapies
Intellicell Biosciences, Inc.
4.10 - (0.00%)
Intraday 3 Month 6 Month 1 Year
The collaboration with Millipore is expected to streamline the development of IntelliCell’s tissue processing centers throughout the United States as it continues to expand and experience growth in demand for the cells it is able to source from fatty tissue.
As we understand it, the company is rapidly expanding the number of centers throughout the United States and multiple positive announcements should follow. These very unique centers will offer patients the opportunity to use their own adipose (fat) stem cells for treatments as prescribed by their own doctors. Under FDA 361, patients are allowed to use their own stem cells for just about any indication, so long as the use of those cells is autologous (a situation in which the donor and recipient are the same person), the stem cells are minimally manipulated, and the procedure takes place during the same office visit. Even without FDA approval- which can take years- IntelliCell™ BioScience aims to work within FDA 361 guidelines and claims that they are fully FDA compliant on their website and presentation materials.
As we told you in our report, this company represents a game changing opportunity for U.S. based patients to undergo various stem cell therapies using their own stem cells without having to travel abroad or wait for further FDA approvals.
We expect that this company- already one of the only true revenue generating stem cell plays in the market- will surpass the $30+ million in revenues generated last year by a privately held company based in Plymouth, Mass called Harvest Technologies Corporation. That company was in the process of commercializing a far more painful (and arguably less effective), point-of-care technology with doctors. Using the Harvest Technology platform, physicians harvested stem cells from a patient’s own bone marrow. Harvest was recently acquired by a U.S. subsidiary of Japan’s Terumo Corporation — one of the world’s leading medical device manufacturers with $3.4 billion in sales and operations in more than 160 countries in a stock for stock transaction worth $70 million.
The market potential for IntelliCell BioSciences is far more attractive, and we are hearing rumors that various sports franchises may be looking to treat the injuries of pro athletes using the IntelliCell platform within the offices of their own team doctors. No surprise if true, since they have pro sports teams physicians on their advisory board.
The use of autologous adipose stem cells for a growing variety of indications may appear new and exciting in medicine here in the U.S, but the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the U.S. FDA published its laws on autologous stem cells the field has expanded rapidly. If you are looking for a stem cell play that isn’t going to make you wait 5+ years for FDA approval, this may be it.
Said IntelliCell Chairman and CEO, Dr. Steven Victor about this week’s news development: ”This is a phenomenal step in the right direction for our company and we welcome the opportunity to work with Millipore. The exclusive agreement with Millipore to supply and sell their cutting-edge guava flow cytometer, combined with our proprietary process which has achieved unprecedented yields of stromal vascular fraction without the use of chemical additives such as enzymes, gives us a highly significant advantage in creating the gold standard for the separation of SVF from fat. As the only company to use precise methods of counting cells and checking specimens for cell viability, dead cells, or debris, this is yet another milestone in our quest to become market leader in the area of separation of SVF, which greatly differentiates us from all other companies that manufacture these cells.”
Again. This company is a game changer for the entire stem cell sector. Start your own DD and read more about it ahead of others and more positive developments.
The PAWS Pet Company, Inc. provides innovative pet services
According to Hoovers, the U.S. veterinary services industry has annual revenues estimated at $25 billion.
"This is an important step in the development of the Company," said Dan Wiesel, Chairman and CEO of The PAWS Pet Company. "This exclusive world-wide license extends our service offering beyond the pet transportation marketplace, into the fast growing market for regenerative medicine for animals. Through our trusted position with both Pet Parents and Veterinarians, we will introduce a technology that we believe will improve the wellbeing of pets."
Dr. Jeff Werber, Director of Veterinary Services with The PAWS Pet Company, commented, "SVF is a proven treatment for a number of conditions including osteoarthritis, tendon repair, ligament injuries and other traumatic and degenerative diseases. The higher cell count from a smaller tissue sample means that Pets have a faster road to recovery with SVF compared to legacy enzyme-based stem cell treatments." - See more at: http://www.007stockchat.com/forum/large-caps/svfc-intellicell-biosciences-inc/limit/20/offset/0#sthash.Ze6om4vG.dpuf
How about another Resume for one of our Board Dr.s:
Intellicell Biosciences Company believes the market for non-enzymatic stromal vascular therapy for the professional sports medicine market is in excess of $1 Billion
Frederic Nicola, MD from D.I.S.C. Sports & Spine Center, who is the team doctor for the Oakland Raiders and Los Angeles Kings. - See more at: http://investorstemcell.com/stem-cell-research/intellicell-biosciences-inc-announces-the-addition-to-medical-advisory-board
Frederic G. Nicola, M.D.
Diplomate, American Board of Orthopedic Surgery
Member, American College of Occupational and Environmental Medicine
Specializing in Orthopedic Surgery and Sports Medicine
Joint Reconstruction and Arthroscopy
http://www.garlandpr.com/Nicola%20CV.pdf
Another Board member who is learning under Dr. James Andrews
Joshua G. Hackel M.D.
Primary Care Sports Medicine| Andrews Primary Care Sports Medicine
Dr. Joshua Hackel is a primary care sports medicine physician at The Andrews Institute, an affiliate of Baptist Health Care. Because he's an employed physician, Dr. Hackel is also a proud part of the Baptist Medical Group network of quality, caring physicians serving the greater Pensacola area.
Medical Education
American University of the Caribbean
Internship
Columbus Regional Medical Center
Residency
Columbus Regional Medical Center
Fellowship
American Sports Medicine Institute (ASMI) with Dr. James Andrews
Board Certifications
Sports Medicine
Family Practice
Major Publications
Hackel JG, Nicolais V, Adolescent with Rash, Photo Quiz. Am Fam Physician, August 2004
Hackel JG, Verma S, Syncope in Athletes: A Guide to Getting Them Back On Their Feet. The Journal of Family Practice, July 2007; 56(7):545-550.
Hackel JG, Asthma Overview. Athletic Therapy Today, 2004; 9(2):28-29.
Andrews JR, Hackel JG. The Thrower’s Exostosis Pathophysiology and Management. Techniques in Shoulder and Elbow Surgery, 2004; 5(1):44-50.
Scholarly Service Honors
Fellow, American Academy of Family Physicians
Academic Appointments
Clinical Associate Professor Florida State School of Medicine
Clinical Associate Professor University of West Florida
Society Memberships
American Medical Society of Sports Medicine
American College of Sports Medicine
American Medical Association
Florida Medical Association
Team Affiliations
Northview High School team physician
University of West Florida athletics team physician
IntelliCell BioSciences Announces Frederick Frank as Executive Advisor to Board of Directors
Dr. Steven Victor, CEO of IntelliCell, stated "We are very pleased to have Mr. Frank join our organization and gain access to his biotechnology expertise and leadership. He has made a tremendous impact on our industry and specifically for the companies he has chosen to be affiliated with. We look forward to his counsel as we strive to achieve new landmarks in regenerative medicine."
Added Mr. Frank "Like many heralded advances in the life sciences field, the early promise and potential creates pronounced enthusiasm. Often the realization of that promise takes longer and is more complex than forecasted. And, inevitably, disappointment sets in. The promise of utilizing therapeutic stem cells is just such an example. But now it's here. Under the leadership of Dr. Steven Victor at IntelliCell BioSciences, the promise of tomorrow is a reality today."
Mr. Frank joined Peter J. Solomon in 2009 from Barclays Capital where he was Vice Chairman. He began his investment banking career at Smith, Barney & Co. Inc. in 1958, where he attained the positions of Co-Head of Research, Vice President and Director. Subsequently he joined Lehman Brothers, Inc., in 1969, as a partner. At Lehman, Mr. Frank provided investment banking services to an extensive number of companies in the pharmaceutical, biotechnology, healthcare services, medical device and nutraceutical industries, and was involved in hundreds of financings, strategic alliances and merger and acquisition transactions in the global healthcare industry. Mr. Frank is a director of Landec Corporation, a publicly-traded material science company, and formerly a director of Pharmaceutical Product Development, Inc., a publicly-traded contract research organization. Mr. Frank previously served as Chairman of the Board of Epix Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. He is Chairman of the National Genetics Foundation, a past director of the Salk Institute, a member of the Pharmaceutical Executive Magazine advisory board and the Journal of Life Sciences, the former Chairman of the Board of The Irvington Institute for Immunological Research, a former member of the Advisory Board of The Harvard School of Public Health, a past member of the advisory board of the Johns Hopkins Bloomberg School of Public Health and he serves on the Advisory Board of the Massachusetts Institute of Technology Center for Biomedical Innovation. He serves on the Yale School of Management Advisory Board. Mr. Frank holds a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
http://www.bafitis.com/stem_cell_therapy_bafitis.asp
WHAT CONDITIONS HAVE BEEN TREATED BY ADIPOSE-DERIVED STEM CELLS?
The United States has been slightly behind in the clinical use of stem cells, but veterinarians have been using equine stem cells derived from fat to correct aging or damaged tendons in horses for over seven years with amazing results! In humans, stem cells have been utilized as follows in the United States:
a. Dermal injections for dermal regeneration with improved lines and wrinkles.
b. Dermal injections for acne scars.
c. Dermal injections for burns and ulcerated wounds.
d. Addition of stem cells to harvested fat for greater take, regeneration, and volumizing of the face and body.
e. These cells have also been successfully utilized in the knee, elbow, and hands in terms of injections for arthritis.
f. Knee injections for cartilage repair or improvement for cartilage loss/ damage.
A quote from Dr. James Andrews:
“I am dramatically impressed with IntelliCell’s proprietary non-enzymatic method for manufacturing Stromal Vascular Fraction from a person’s own adipose tissue,” said Dr. Andrews. “The amount of SVF cells that this process creates will enable physicians to treat sports injuries without the need for culturing the cells or adding enzymes. We are looking forward to employing this process at our own Institute and to conduct further research with the IntelliCell team on this exciting regenerative medicine.”
http://www.businesswire.com/news/home/20120109006237/en/CORRECTING-REPLACING-IntelliCell-Biosciences-Announces-Addition-World
Dr. James Andrews treated Adrian Peterson and Robert Griffin III with Stem cells in their recent surgeries. Dr. Andrews sits on our Medical Advisory Board and believes Stem Cells are the future!
There are physicians who have also utilized stem cells via IV drip for osteoarthritis and improvement in pain from inoperable joint/spine disease.
CJ,
I sent email to Anna Rhodes and Steven Victor yesterday in regards to future up-listing to a big board again and IND question. Below is his response with my name removed:
From: Steven Victor <rhodesvictor@aol.com>
To: Anna Rhodes <arhodes@intellicellbiosciences.com>,
Date: 06/26/2013 06:28 AM
Subject: Intellicell
Thank you for taking a stake in Intellicell. We are committed to bringing all shareholders value and look to advance the company to one of the big boards as soon as we can and we are always developing new and better technology and always file patents to protect our IP and as stated in our website we are looking to doing FDA IND for different disease entities.
We have exciting news coming in the near future for all our shareholders.
Steven Victor MD
Chairman/CEO
Intellicell Biosciences Inc
460 Park Avenue 17th Floor
New York, NY 10022
212-249-3050 Regen Medical PC
Cell 917-459-8252
Svictor@intellicellbiosciences.com
www.intellicellbiosciences.com
Www.regenmedicalpc.com
Www.victordermatologyandrejuvenation.com
Intellicell's partner in Canada.
The RegenaStem Cellular Treatment Centers will utilize the patented IntelliCell Inc. proprietary
procedures to harvest and deliver to patients Autologous Homologous SVF to treat degenerative joint
disease of the upper and lower limb with a focus on the hip, shoulder and knee.
There is a nice case study in there as well about Regeneration of human bones in hip osteonecrosis
and human cartilage in knee osteoarthritis with
autologous adipose-tissue-derived stem cells (SVFC):
a case series
http://www.regenastem.com/documents/RegenaStem_Health_Canada_Compliance_Proposal_Oct24.pdf
Won't hold us Down too much longer with all of the things SVFC is working on.
IntelliCell BioSciences, Inc. Announces Collaborative Agreement With University Of Florida On Stem Cell And Tissue Repair Research
IntelliCell BioSciences, Inc. Signs Technology Licensing Agreement With Stem Cells 21 Thailand
IntelliCell BioSciences, Inc. Announces Study Published In The Journal of Implant & Advanced Clinical dentistry
IntelliCell BioSciences, Inc. Signs Exclusive Supply And Sale Agreement With Millipore Corporation
IntelliCell BioSciences, Inc. Announces It Has Opened Adipose Tissue Processing Center In West Palm Beach, Florida
The PAWS Pet Company, Inc. Announces Exclusive License Agreement With IntelliCell BioSciences, Inc
IntelliCell BioSciences, Inc. Announces It Has Opened An Adipose Tissue Processing Center In New Orleans
IntelliCell BioSciences, Inc. To Open Tissue Processing Center In Baton Rouge, LA
IntelliCell BioSciences, Inc. Announces Validation Of Technology By Merck Subsidiary
Did anyone know that svfc signed exclusive with PAWS? What a huuuuggggee Market! people care a lot for their pets.
The PAWS Pet Company, Inc. Announces Exclusive License Agreement With IntelliCell BioSciences, Inc
The PAWS Pet Company, Inc. (OTCQB: PAWS) (OTCPK: PAWS) or “the Company”, the innovative pet services company, today announced it has entered into an exclusive license agreement with IntelliCell BioSciences, Inc., “IntelliCell”, (OTCPK: SVFC) a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells. Per the terms of the agreement, The PAWS Pet Company is to exclusively market and sell IntelliCell’s SVF solution in the veterinary market.
According to Hoovers, the U.S. veterinary services industry has annual revenues estimated at $25 billion.
“This is an important step in the development of the Company,” said Dan Wiesel, Chairman and CEO of The PAWS Pet Company. “This exclusive world-wide license extends our service offering beyond the pet transportation marketplace, into the fast growing market for regenerative medicine for animals. Through our trusted position with both Pet Parents and Veterinarians, we will introduce a technology that we believe will improve the wellbeing of pets.”
Dr. Steven Victor, Chairman and CEO of IntelliCell added, “We are pleased to be working with The PAWS Pet Company in bringing our leading SVF solution to the treatment of animals. The benefits of SVF in providing stem cell counts and viability checks for each specimen processed, as well as enhanced quality and quantity of the stem cells produced, will now be available to pets.”
Dr. Jeff Werber, Director of Veterinary Services with The PAWS Pet Company commented, “SVF is a proven treatment for a number of conditions including osteoarthritis, tendon repair, ligament injuries and other traumatic and degenerative diseases. The higher cell count from a smaller tissue sample means that Pets have a faster road to recovery with SVF compared to legacy enzyme-based stem cell treatments.”
Good Job CJ keeping this in front of new investors!
Have a good Holiday
Thanks you for our Freedom and all you do serving this Country! Good weekend for all to remember that.
GLTA
I think he was being sarcastic about a poster saying FIT" was the place to be. CC is on our side.
GLTA
I am loving the fact that I can keep buying at these prices! I know there are few here that have lost patience and have turned negative, be patient and relax as this is the penny stocks. Did you really think you could buy millions of shares one day for .001 and sell it for $1.00 a couple weeks later? Just know that the same shares are being flipped every week between .0024 and .0038. We are just waiting on news, like 6 million in sales last Q, or uplisting, chill lifted, BB store shelves, Walgreens and Drugstore.com, Health Enrich being a potential for a sell off to big box pet Co. How about Global Sales? There is so much that will happen with this Company and by far one of the best long term stocks in pinks. Not to many of us could take over a de ad business and bring it to where it is now in a year period. Nick has done great and thanks for getting back to me with answers to my emails. So, sell now and regret later, I will be waiting to buy.
BJames15, thanks of the updates
MDIN